menu
    • menu
    [{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"anti-inflammatory\/analgesic agents (ibuprofen type)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Haiphong University of Medicine and Pharmacy","sponsor":"Daewon Pharm. Co., Ltd | Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"COXs | NET | \u03bc","graph1":"Neurology","graph2":"Phase I","graph3":"Haiphong University of Medicine and Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Haiphong University of Medicine and Pharmacy \/ Daewon Pharm. Co., Ltd | Big Leap Research","highestDevelopmentStatusID":"6","companyTruncated":"Haiphong University of Medicine and Pharmacy \/ Daewon Pharm. Co., Ltd | Big Leap Research"},{"orgOrder":0,"company":"Haiphong University of Medicine and Pharmacy","sponsor":"Daewon Pharm. Co., Ltd | Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pelubiprofen","moa":"COXs | NET | \u03bc","graph1":"Undisclosed","graph2":"Phase I","graph3":"Haiphong University of Medicine and Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Haiphong University of Medicine and Pharmacy \/ Daewon Pharm. Co., Ltd | Big Leap Research","highestDevelopmentStatusID":"6","companyTruncated":"Haiphong University of Medicine and Pharmacy \/ Daewon Pharm. Co., Ltd | Big Leap Research"}]

    Find Clinical Drug Pipeline Developments & Deals for Pelubiprofen

    Menu

    Pelubiprofen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Haiphong University of Medicine and Pharmacy

                            Country arrow
                            FNCE
                            Not Confirmed

                            Haiphong University of Medicine and Pharmacy

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelubiprofen

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Daewon Pharm. Co., Ltd | Big Leap Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults

                            Details : DW-1021 (Pelubiprofen) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Pain.

                            Product Name : DW-1021

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 11, 2025

                            Lead Product(s) : Pelubiprofen

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Daewon Pharm. Co., Ltd | Big Leap Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Haiphong University of Medicine and Pharmacy

                            Country arrow
                            FNCE
                            Not Confirmed

                            Haiphong University of Medicine and Pharmacy

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelubiprofen

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Daewon Pharm. Co., Ltd | Big Leap Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of DW-1021 with Pelubi CR & Zytram CR Under Fasting Conditions

                            Details : DW-1021 (Pelubiprofen) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : DW-1021

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2025

                            Lead Product(s) : Pelubiprofen

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Daewon Pharm. Co., Ltd | Big Leap Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            FNCE
                            Not Confirmed

                            Daewon Pharm. Co., Ltd

                            South Korea arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelubiprofen

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

                            Details : Pelubiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dysmenorrhea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2020

                            Lead Product(s) : Pelubiprofen

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth